Related Experiment Video
Updated: Jun 25, 2026
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
13.5K
Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update.
Katherine S Virgo1, R Bryan Rumble2, Ronald de Wit3
1Emory University, Atlanta, GA.
Summary
New guidelines recommend androgen deprivation therapy (ADT) combined with docetaxel, abiraterone, enzalutamide, or apalutamide for metastatic prostate cancer. These treatments are now standards of care for advanced disease.
Area of Science:
- Oncology
- Urology
- Clinical Practice Guidelines
Background:
- Prostate cancer management requires updated guidelines for initial hormonal therapy in advanced, recurrent, or metastatic noncastrate disease.
- Expert panel reviewed systematic literature, including phase III trials and meta-analyses, to inform recommendations.
Framework:
- ASCO guidelines updated based on systematic literature review.
- Recommendations approved by Expert Panel and ASCO Clinical Practice Guidelines Committee.
Implementation:
- Androgen deprivation therapy (ADT) plus docetaxel, abiraterone, enzalutamide, or apalutamide are standards of care for metastatic noncastrate prostate cancer.
- Consider ADT with abiraterone and prednisolone for locally advanced nonmetastatic prostate cancer post-radiotherapy.
- Offer immediate or intermittent ADT for nonmetastatic disease based on risk and patient factors; active surveillance for low-risk recurrent disease.
Implications:
- These updated guidelines provide a framework for optimal initial hormonal management in advanced prostate cancer.
- The recommendations aim to improve treatment strategies and outcomes for patients with noncastrate advanced prostate cancer.
- Further research may refine the use of specific agents and combinations in the noncastrate setting.
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...